Using the galectin-3 test to predict mortality in heart failure patients: A systematic review and meta-analysis

Yueh Sheng Chen, Weng Tein Gi, Tin Yun Liao, Meng Tse Gabriel Lee, Si Huei Lee, Wan Ting Hsu, Shy Shin Chang, Chien Chang Lee

研究成果: 雜誌貢獻回顧型文獻同行評審

21 引文 斯高帕斯(Scopus)

摘要

Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. Results: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. Conclusion: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.

原文英語
頁(從 - 到)329-342
頁數14
期刊Biomarkers in Medicine
10
發行號3
DOIs
出版狀態已發佈 - 3月 2016
對外發佈

ASJC Scopus subject areas

  • 藥物發現
  • 臨床生物化學
  • 生物化學(醫學)

指紋

深入研究「Using the galectin-3 test to predict mortality in heart failure patients: A systematic review and meta-analysis」主題。共同形成了獨特的指紋。

引用此